Company Filing History:

16 out of 1,306

Case Western Reserve University

patents

5 out of 1,036

The Cleveland Clinic Foundation

patents

where one patent can have more than one assignee

Years Active: 2018-2023

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11574404 - Predicting recurrence and overall survival using radiomic features correlated with PD-L1 expression in early stage non-small cell lung cancer (ES-NSCLC) (2023-02-07),

2. 11350901 - Recurrence prognosis and prediction of added benefit of adjuvant chemotherapy in early stage non-small cell lung cancer with radiomic features on baseline computed tomography (2022-06-07),

3. 11055844 - Predicting response to immunotherapy using computer extracted features of cancer nuclei from hematoxylin and eosin (HandE) stained images of non-small cell lung cancer (NSCLC) (2021-07-06),

4. 10956795 - Predicting recurrence in early stage non-small cell lung cancer (NSCLC) using spatial arrangement of clusters of tumor infiltrating lymphocytes and cancer nuclei (2021-03-23),

5. 10950351 - Methods and apparatus for predicting benefit from immunotherapy using tumoral and peritumoral radiomic features (2021-03-16),

6. 10902256 - Predicting response to immunotherapy using computer extracted features relating to spatial arrangement of tumor infiltrating lymphocytes in non-small cell lung cancer (2021-01-26),

7. 10846367 - Predicting recurrence in early stage non-small cell lung cancer (NSCLC) with integrated radiomic and pathomic features (2020-11-24),

8. 10839513 - Distinguishing hyperprogression from other response patterns to PD1/PD-L1 inhibitors in non-small cell lung cancer with pre-therapy radiomic features (2020-11-17),

9. 10575774 - Predicting immunotherapy response in non-small cell lung cancer with serial radiomics (2020-03-03),

10. 10492723 - Predicting immunotherapy response in non-small cell lung cancer patients with quantitative vessel tortuosity (2019-12-03),

11. 10458895 - Predicting response to pemetrexed chemotherapy in non-small cell lung cancer (NSCLC) with baseline computed tomography (CT) shape and texture features (2019-10-29),

12. 10441225 - Predicting disease recurrence following trimodality therapy in non-small cell lung cancer using computed tomography derived radiomic features and clinico-pathologic features (2019-10-15),

13. 10441215 - Predicting immunotherapy response in non-small cell lung cancer with serial quantitative vessel tortuosity (2019-10-15),

14. 10346975 - Computerized analysis of computed tomography (CT) imagery to quantify tumor infiltrating lymphocytes (TILs) in non-small cell lung cancer (NSCLC) (2019-07-09),

15. 10078895 - Prediction of recurrence of non-small cell lung cancer with tumor infiltrating lymphocyte (TIL) graphs (2018-09-18),

Title: Innovations in Cancer Prognosis: The Contributions of Vamsidhar Velcheti

Introduction

Vamsidhar Velcheti is a notable innovator based in Pepper Pike, Ohio, recognized for his significant contributions to the field of medical imaging and cancer prognosis. With a remarkable portfolio of 16 patents, he focuses primarily on developing technologies that enhance predictions related to cancer recurrence and treatment efficacy.

Latest Patents

Among his latest patents is the innovation titled "Predicting recurrence and overall survival using radiomic features correlated with PD-L1 expression in early stage non-small cell lung cancer (ES-NSCLC)." This patent describes a method where a processor is controlled to perform operations including accessing a digitized image of cancerous tissue, extracting radiomic features correlated with PD-L1 expression, and applying machine learning algorithms to predict the probability of cancer recurrence.

Another significant patent is related to "Recurrence prognosis and prediction of added benefit of adjuvant chemotherapy in early stage non-small cell lung cancer with radiomic features on baseline computed tomography." This invention aims to generate prognosis for NSCLC recurrence and assess the potential benefits of adjuvant chemotherapy by analyzing radiological images and extracting relevant radiomic features.

Career Highlights

Throughout his career, Vamsidhar has worked with prestigious institutions such as Case Western Reserve University and The Cleveland Clinic Foundation. His role in these organizations has allowed him to merge research with practical applications, advancing the understanding of cancer prognosis.

Collaborations

In his journey of innovation, Vamsidhar has collaborated with esteemed peers, including Anant Madabhushi and Xiangxue Wang. These collaborations have proven instrumental in enhancing the precision of his research and the development of groundbreaking technologies in cancer diagnostics.

Conclusion

Vamsidhar Velcheti's contributions to the field of cancer prognosis through his patents highlight the vital intersection of innovation and healthcare. His dedication to improving clinical outcomes for patients with non-small cell lung cancer sets a precedent for future research and development in medical technology.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com

1 patent pending (EPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.